At the Genitourinary Cancers Symposium yesterday afternoon, new data were presented from Phase II studies of tasquinimod and cabozatinib (XL184) … READ MORE …
Filed under: Drugs in development, Management | Tagged: cabozatinib, ipilimumab, tasquinimod, XL184 | 1 Comment »
THE "NEW" PROSTATE CANCER INFOLINK 